Targeting the histone methylome as a therapeutic strategy has quickly captured the interest of developers worldwide, due to the genetic and over-expression abnormalities displayed in a variety of human cancers, as well as the chemically tractable nature of modifying enzymes. Adding to the more established series of histone methyltransferase targets, histone demethylases of both JmjC and CoREST domains have also advanced into clinical development and are now showing favorable clinical outcomes. Notably, a surge of interest and success in developing inhibitors against arginine methyltranslferase enzymes has substantially deepened the possibilities of regulating chromatin environments via histone methylation, and thereby expanding this already robust target space.
Cambridge Healthtech Institute will once again convene leaders in epigenetic drug development to further our understanding of the role aberrant histone methylation plays in disease, to evaluate lead and clinical compounds by developers, and to introduce novel chemical matter for further development.
Who should attend: Executives, Directors, Managers, Group Leaders and Senior Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Drug Discovery, Pre-Clinical Research and Development, Molecular/Cell Biology, Biochemistry, Chemical Genomics/Biology, Structural Biology, Medicinal Chemistry, Pharmacology and Synthetic Chemistry.
Topics will include, but are not limited to:
- Understanding HMTs and HDMs in Disease
- Genetic Abnormalities of HMTs and HDMs in Disease
- Regulatory Mechanisms Leading to Disease
- Technological Advances for Interrogating the Histone Methylation, Histone Methyltransferases and Demethylases in vivo
- Discovery to Lead
- Strategies for Discovery and Development of Novel Chemical Matter, Including: High-Throughput Screening, Virtual Screening, Fragment/Structure-Based Design, Chemoinformatic Approaches
- Functional and Structural Analysis of HMTs and HDMs
- Structure Activity Relationships
- Optimization to Lead
- Novel HMT and HDM Inhibitors
- Pre-Clinical and Clinical Development
- Updates on HMT and HDM Programs in Preclinical and Clinical Stages
- PK/PD - in vitro and in vivo Target Binding Kinetics
- Mechanism of Action
- Assessing Efficacy and Toxicity
- Disease Relevant Pre-Clinical Models and Biomarkers
If you are interested in speaking, click here to submit a speaking proposal.
The deadline for submission is March 11, 2015.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Cambridge Healthtech Institute
T: (+1) 781-972-5454
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483